CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of “Moderate Buy” from Brokerages

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.3571.

Several equities research analysts have commented on the company. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Zacks Research lowered CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Leerink Partners raised their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd.

CAMP4 Therapeutics Stock Down 3.2%

Shares of NASDAQ CAMP opened at $3.01 on Friday. The firm has a market cap of $156.31 million, a price-to-earnings ratio of -1.28 and a beta of 0.10. The company’s 50-day simple moving average is $4.16 and its 200-day simple moving average is $4.47. CAMP4 Therapeutics has a 52-week low of $1.32 and a 52-week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Equities research analysts anticipate that CAMP4 Therapeutics will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. EcoR1 Capital LLC purchased a new stake in CAMP4 Therapeutics during the 4th quarter valued at about $1,992,000. Bridgeway Capital Management LLC acquired a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $36,000. Jefferies Financial Group Inc. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $61,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.